Clinical Pharmacokinetics of CNS Medications in Microgravity: A Review of Safety and Efficacy Gaps

Background: The spaceflight of humans is now expanded to missions in deep space as is the case in the Artemis programme and future Mars transit missions, requiring a strict reassessment of pharmacotherapy in microgravity. Central nervous system (CNS) drugs such as hypnotics, anxiolytics, antidepressants, antipsychotics and antiemetics are a crucial part of the space formulary, but their pharmacokinetic performance in microgravity has been scarcely characterized. Objective: This review critically evaluates the current knowledge about the clinical pharmacokinetics of CNS drugs in microgravity, and in particular, the identification of critical safety and efficacy gaps within absorption, distribution, metabolism and excretion (ADME). Methods: A literature review of peer-reviewed articles, space agency technical reports, and conference papers was performed on a narrative basis. Key words were pharmacokinetics, microgravity, spaceflight, CNS drugs, sleep medication, anxiety medication, drug metabolism, drug absorption. Where the inflight human data were not available, ground based analogue data of head down tilt bed rest and dry immersion studies were included. Key Findings: Microgravity affects each ADME domain in unique ways: delayed gastric emptying, cephalad fluid shift, hepatic CYP450 enzyme suppression impairs metabolic clearance of most CNS drugs classes. Renal clearance of toxic metabolites is also delayed because of hemodynamic changes. PK issues become even more problematic because most of the ISS formulary drugs have terrestrial shelf lives of 36 months or less which is totally unsuitable for Mars transit missions. Conclusions: Current CNS dosing schedules cannot be considered as safe or efficacious in long duration spaceflight. Future studies should focus on inflight PK studies with noninvasive micro sampling, microgravity-modified physiologically based pharmacokinetic (PBPK) modelling, pre-flight pharmacogenomic screening and setting up space-specific pharmacopeial standards. One of the key conditions to human exploration of deep space in the future is the reliability of CNS pharmacotherapy, the key to the success of the exploration.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-20
DOI
https://doi.org/10.5281/zenodo.24403868
Primary Topic
Spaceflight effects on biology
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Clinical Pharmacokinetics of CNS Medications in Microgravity: A Review of Safety and Efficacy Gaps

Jaweria Afzal
1 links
Zenodo (CERN European Organization for Nuclear Research)
Spaceflight effects on biology
preprint

Clinical Pharmacokinetics of CNS Medications in Microgravity: A Review of Safety and Efficacy Gaps

Jaweria Afzal
preprint en

Abstract

Background: The spaceflight of humans is now expanded to missions in deep space as is the case in the Artemis programme and future Mars transit missions, requiring a strict reassessment of pharmacotherapy in microgravity. Central nervous system (CNS) drugs such as hypnotics, anxiolytics, antidepressants, antipsychotics and antiemetics are a crucial part of the space formulary, but their pharmacokinetic performance in microgravity has been scarcely characterized. Objective: This review critically evaluates the current knowledge about the clinical pharmacokinetics of CNS drugs in microgravity, and in particular, the identification of critical safety and efficacy gaps within absorption, distribution, metabolism and excretion (ADME). Methods: A literature review of peer-reviewed articles, space agency technical reports, and conference papers was performed on a narrative basis. Key words were pharmacokinetics, microgravity, spaceflight, CNS drugs, sleep medication, anxiety medication, drug metabolism, drug absorption. Where the inflight human data were not available, ground based analogue data of head down tilt bed rest and dry immersion studies were included. Key Findings: Microgravity affects each ADME domain in unique ways: delayed gastric emptying, cephalad fluid shift, hepatic CYP450 enzyme suppression impairs metabolic clearance of most CNS drugs classes. Renal clearance of toxic metabolites is also delayed because of hemodynamic changes. PK issues become even more problematic because most of the ISS formulary drugs have terrestrial shelf lives of 36 months or less which is totally unsuitable for Mars transit missions. Conclusions: Current CNS dosing schedules cannot be considered as safe or efficacious in long duration spaceflight. Future studies should focus on inflight PK studies with noninvasive micro sampling, microgravity-modified physiologically based pharmacokinetic (PBPK) modelling, pre-flight pharmacogenomic screening and setting up space-specific pharmacopeial standards. One of the key conditions to human exploration of deep space in the future is the reliability of CNS pharmacotherapy, the key to the success of the exploration.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Spaceflight effects on biology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Clinical Pharmacokinetics of CNS Medications in Microgravity: A Review of Safety and Efficacy Gaps — Jaweria Afzal · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS